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Structured diet and exercise guidance in
pregnancy to improve health in women
and their offspring: study protocol for the
Be Healthy in Pregnancy (BHIP) randomized
controlled trial
Maude Perreault1, Stephanie A. Atkinson1* , Michelle F. Mottola2, Stuart M. Phillips3, Keyna Bracken4,
Eileen K. Hutton5, Feng Xie6, David Meyre6,7, Rita E. Morassut6, Harry Prapavessis2, Lehana Thabane6 and the BHIP
Study team

Abstract
Background: Evidence from epidemiological and animal studies support the concept of programming fetal, neonatal,
and adult health in response to in utero exposures such as maternal obesity and lifestyle variables. Excess gestational
weight gain (GWG), maternal physical activity, and sub-optimal and excess nutrition during pregnancy may program
the offspring’s risk of obesity. Maternal intake of dairy foods rich in high-quality proteins, calcium, and vitamin D may
influence later bone health status. Current clinical practice guidelines for managing GWG are not founded on
randomized trials and lack specific “active intervention ingredients.” The Be Healthy in Pregnancy (BHIP) study is a
randomized controlled trial (RCT) designed to test the effectiveness of a novel structured and monitored Nutrition +
Exercise intervention in pregnant women of all pre-pregnancy weight categories (except extreme obesity), delivered
through prenatal care in community settings (rather than in hospital settings), on the likelihood of women achieving
recommended GWG and a benefit to bone status of offspring and mother at birth and six months postpartum.
Methods: The BHIP study is a two-site RCT that will recruit up to 242 participants aged > 18 years at 12–17 weeks of
gestation. After baseline measures, participants are randomized to either a structured and monitored Nutrition +
Exercise (intervention) or usual care (control) program for the duration of their pregnancy. The primary outcome of the
study is the percent of women who achieve GWG within the Institute of Medicine (IOM) guidelines. The secondary
outcomes include: (1) maternal bone status via blood bone biomarkers during pregnancy; (2) infant bone status in
cord blood; (3) mother and infant bone status measured by dual-energy absorptiometry scanning (DXA scan) at six
months postpartum; (4) other measures including maternal blood pressure, blood glucose and lipid profiles, % body
fat, and postpartum weight retention; and (5) infant weight z-scores and fat mass at six months of age.
Discussion: If effective, this RCT will generate high-quality evidence to refine the nutrition guidelines during
pregnancy to improve the likelihood of women achieving recommended GWG. It will also demonstrate the
importance of early nutrition on bone health in the offspring.
Trial registration: ClinicalTrials.gov, NCT01689961 Registered on 21 September 2012.
Keywords: Nutrition, Exercise, Randomized controlled trial, Pregnancy, Bone, Infancy, Developmental origins of health
and disease, Proteins, Dairy foods, Gestational weight gain
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Background
Consequences of excess gestational weight gain (GWG)

The documented adverse sequelae of excess GWG for
both mother and child include undesirable pregnancy/
birth outcomes and/or later health outcomes that are likely
to impose a substantive downstream burden on healthcare
costs [1]. The most common adverse effect of excessive
GWG on maternal health is weight retention (five months
and even up to three years postpartum) [2–4]. Mothers
entering subsequent pregnancies at a higher weight are at
greater risk for long-term obesity and future co-#morbidties such as diabetes and cardiovascular disease [5, 6]. The
emerging evidence of developmental origins of health and
disease implicates the impact of mothers’ health during
pregnancy on “programming” of the growing fetus in utero
to develop adverse health outcomes [7, 8]. Maternal excess
GWG has been reported as the strongest predictor of
obesity in the offspring [9–11].
The use of low-fat dairy foods as the source of protein
in pregnancy is proposed based on studies in animals [12]
and humans [13–15] that provide support for the putative
effects of components of dairy foods such as calcium and
leucine as anti-adipogenic and pro-lipolytic agents.
Consumption of high dairy protein may not only benefit
GWG but also improve other maternal pregnancy outcomes such as dysglycemia, elevated blood pressure, blood
lipid profiles, and risk of pre-eclampsia, the latter due to
higher intake of calcium and vitamin D [16].
Guidelines for GWG exist and have been interpreted
for practice in Canada [17, 18]. Until there is evidence of
effective population level interventions to assist women
in achieving healthy weights, programs aimed at interventions during pregnancy to improve weight management and pregnancy outcomes are a starting point.
Pregnancy has been described as a “teachable moment”
for weight control and obesity prevention in women
[19]. The most convincing approach to achieve reduction in GWG is the combination of physical activity and
diet counseling, preferably in combination with weight
monitoring [1, 20, 21]. Yet current clinical practice
guidelines for managing GWG are not founded on randomized trials and lack specific “active intervention ingredients” [21] that are proven effective in achieving
target GWG.
Maternal programming of bone health

Findings from epidemiological and animal studies support a role for the programming of fetal, neonatal, and
adult bone outcomes in response to exposures during
pregnancy such as maternal nutrition and other lifestyle
variables [22–25]. In three longitudinal observational
studies, maternal intake of dairy foods during pregnancy
was associated with higher bone mass in offspring aged
6–16 years [26–28]. In prospective cohort studies,
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maternal physical activity level has also been positively
associated with infant bone mass and geometry at birth
[29, 30]. Being born with optimal bone mass may have
long-term benefits since childhood bone mass tracks until
skeletal maturity, when peak bone mass is achieved [31].
Collectively, these findings suggest that bone mass during
childhood and adolescence may be predictive of an individual’s risk for osteoporosis, as peak bone mass is a
strong predictor of osteoporotic fracture later in life [32].
To date, only one randomized controlled trial (RCT)
in a small sample (N = 36) investigated the effect of dairy
product supplementation on bone mineral density
(BMD) and bone turn-over in pregnant women and
these women entered pregnancy with a habitually low
calcium intake [33]. The study showed a beneficial effect
of increased milk consumption on maternal bone mass
density at the spine and on suppression of bone resorption when measured at 6 ± 1 weeks postpartum. While
promising, further studies are needed with larger sample
sizes and evaluation of bone health outcomes in the offspring. In addition, no study to date has investigated the
impact of dairy product supplementation during pregnancy on bone health outcomes of women after delivery.
Informed by our recent clinical and qualitative research,
as well as existing systematic reviews, we have designed a
RCT comprising several unique features with the objective
of controlling GWG and optimizing bone health of
mother and infant. We will test the effectiveness of a novel
structured and monitored nutrition (high-protein
dairy-based diet) along with an exercise (walking) intervention that is science-based, vetted for feasibility in pregnant women and care providers through focus groups, in
pregnant women of most pre-pregnancy weight categories
(except extreme obesity) in a community setting (as opposed to hospital-based).
Specific objectives and hypothesis

The primary research objective of the Be Healthy in
Pregnancy (BHIP) study is to determine whether introducing a structured and monitored nutrition (high-dairy
protein diet) and exercise (walking) program (intervention) in early pregnancy, compared to standard prenatal
care (control), will increase the number of women
attaining GWG (outcome) within the Institute of Medicine (IOM) recommendations for their pre-pregnancy
body mass index (BMI) sub-category [17].
Secondary objectives include determination of the impact of a maternal high-dairy diet with exercise compared to standard care diet during pregnancy on: (1)
bone status (e.g. blood biomarkers procollagen type I
that contains N-terminal extensions (PINP), C-terminal
telopeptide of type I collagen (CTX-I), insulin-like
growth factor-1 (IGF-1), 25-hydroxyvitamin D
(25(OH)D), and 1,25-dihydroxyvitamin D) in mothers
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during pregnancy; (2) infant bone status at birth via cord
blood; and (3) mother and infant bone status at six
months postpartum by dual energy x-ray absorptiometry
(DXA) scan.
The over-arching hypothesis is that maternal consumption of a high-dairy diet during pregnancy will have
a positive impact on: (1) GWG; (2) bone health status of
the mother during and after pregnancy; and (3) bone
mass and bone size of the offspring, after adjustment for
factors known to influence skeletal status.
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interview according to the criteria list below. Eligible
women are enrolled in the study and sign informed
consent by the end of the first trimester of pregnancy
(i.e. 12–17 weeks of gestation).
Inclusion criteria
 Healthy pregnant women aged > 18 years
 Singleton pregnancy (either nulliparous or

multiparous)
 Able to be randomized to group allocation by 17

Methods/design
Trial design

The BHIP study is a two-arm, two-site prospective RCT.
This study is designed as a prospective superiority trial,
with 1:1 allocation ratio to either the Intervention group
(i.e. Nutrition + Exercise intervention: high-dairy nutrition intervention combined with structured exercise) or
the Control group (i.e. usual care as per National Health
Canada recommendations) during pregnancy. The study
is open-label with blinded endpoints. The study protocol
is described following the standard protocol items: recommendations for interventional trials (SPIRIT) guidelines [34]. See Additional file 1 for the SPIRIT checklist
and Additional file 2 for the WHO trial registration data
set.
The core BHIP trial follows women up to delivery as
the primary outcome relates to GWG. The Bone-BHIP
study is an extension of the core BHIP trial that continues a follow-up of the women and their offspring
until six months after delivery, with the objective to assess maternal and infant bone status. This trial is registered at ClinicalTrial.gov (NCT01689961). The BHIP
trial is conducted by collaborative research teams at
McMaster University (Hamilton, ON) and Western University (London, ON) in Canada. The study takes place
in academic hospitals and community healthcare clinics
in London, Burlington, and Hamilton, Ontario, Canada.
Recruitment is facilitated by healthcare professionals
(e.g. family doctors and midwives) who ask their patients
for consent to be contacted by the BHIP study team, as
well as poster advertisements in midwifery, family practice, and ultrasound clinics, at community sites such as
the YMCA, libraries, and coffee shops, and on Facebook
or Kijiji.
Study recruitment began in January 2013 and is expected to be completed by April 2018, reaching the a
priori calculated sample size of 242 participants for our
primary outcome. All participants who sign consent to
contact forms receive a phone call by study personnel
and are provided a general overview of the study and
expectations using a scripted text. Figure 1 outlines the
participant’s timeline in the BHIP study. Participants
are screened for eligibility during the telephone

weeks and six days of gestation
 Pre-pregnancy BMI < 40 kg/m2
 Planning to deliver at a Hamilton, Burlington, or

London regional hospital or by home birth and
willing to attend research visits at either study site
 Approval of primary care provider to participate in
exercise
 Able to provide signed informed consent
Exclusion criteria
 Not conversant in English
 Known contraindications to exercise as







recommended by the Canadian clinical practice
guidelines for pregnancy [35]
Severe chronic gastrointestinal, heart, kidney, liver,
or pancreatic diseases or conditions
Refusal to consume dairy foods due to intolerance
or dislike
Pre-existing diabetes
Currently smoking and will not discontinue smoking
during the pregnancy
Depression score > 12 on the validated Edinburgh
Depression scale

Randomization: allocation and implementation

Block randomization is used with block sizes of two, four,
and six selected at random, using an online Research Electronic Data Capture (REDCap) randomization service
managed by an independent team in the Biostatistics Unit
at St Joseph’s Healthcare in Hamilton, ON, Canada.
Randomization to the two study arms occurs in a 1:1 ratio
and is stratified by study site and pre-pregnancy BMI
category following IOM guidelines (underweight: BMI
< 18.5, normal weight: BMI 18.5–24.9, overweight: BMI
25.0–29.9, and obese: BMI ≥ 30.0 kg/m2). The eligibility
of participants is confirmed at the first visit, when
baseline data are also collected. The research assistant
randomizes the participant at the second visit to the
study center using an online third-party automatic
randomization system. Once randomized, the research
assistant consents the participant to the appropriate
study arm at a time that is 14–17 weeks/6 days of
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gestation. Assessments, regardless of the study arm,
occur at < 18 weeks of gestation, 26–28 weeks of gestation, 36–38 weeks of gestation, birth, three months
postpartum, and six months postpartum. The intervention arm consists of weekly or biweekly in-person visits
(based on the participant’s preferences) during pregnancy (i.e. from allocation to study group until 36–38
weeks of gestation). Baseline measures (i.e. before
randomization), primary and secondary outcome measures, and other measures assessed during and after
pregnancy are measured in all participants, regardless
of their study group allocation.
The flow diagram (Fig. 2) will be included in future
published results.
This study is open-label due to the nature of the intervention. The study research assistants (data collectors)
administering the personalized Nutrition + Exercise
intervention are not blinded to group allocation. In
addition, the participants are not blinded to their own

Fig. 1 Flow diagram
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group allocation, in order to maximize adherence to the
lifestyle treatment. Mothers randomized to the intervention and control groups are assessed at the study clinic
on different days, to prevent interaction between participants of each study arm. The primary data outcome collector is blinded to group allocation and is conducting
the study visits for all participants, regardless of their
group allocation. To maximize the objectivity of findings, the primary outcome assessor and data analysts/
statistician are blinded to the study allocation and are
not collecting any study data.
Interventions

All participants receive usual care as delivered by their
healthcare practitioner (family physician or midwife)
during pregnancy. In addition, after enrolment in the
RCT and regardless of their group allocation, all participants receive counseling by the study nutritionist on
the latest recommendations by Health Canada as
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Table 1 BHIP study arms
Component

Control arm
Usual care
12–17 to 36–38
weeks of gestation

Intervention arm
Nutrition + Exercise intervention
12–17 to 36–38
weeks of gestation

Gestational
weight gain
(GWG)

Latest recommendation by Health Canada
in terms of GWG [17] and the Pregnancy
Weight Gain Calculator [44]

Latest recommendation by Health Canada in terms of GWG [17]

Nutrition
during
pregnancy

Latest recommendation by Health Canada
in terms of nutrition during pregnancy [74]
and Eating Well with Canada’s Food
Guide [46]

Latest recommendation by Health Canada in terms
of nutrition during pregnancy [74]
Nutrition component of the intervention
1. Individualized nutrition plan with a high protein content: ~ 25%
of energy intake which is within the acceptable macronutrient
distribution range
a. Individualized to each mother’s estimated energy requirement
and calculated using the equation derived in the Dietary Reference
Intake report for women [43] with energy intakes adjusted as
recommended in the second and third trimesters [74]
b. Provided by dairy foods: 4–5 servings of dairy food/d: fresh
low-fat white milk and/or cottage cheese and/or low-fat
Greek yogurt, as implemented in our previous study [38]

Exercise
during
pregnancy

Latest recommendation by Health Canada
in terms of exercise during pregnancy [75]

Latest recommendation by Health Canada in terms of exercise
during pregnancy [75]
Exercise component of the intervention
1. Controlled walking program with the study nutritionist
a. 25 min per session, 3–4 times per week, while increasing the
time by 2 min/week to a maximum of 40 min maintained
until delivery [39]
2. 10,000 steps per day
a. Daily step counts and any other exercise tracked using
a pedometer every day and an exercise log. Also used
as a motivator and self-monitoring device which will also
help improve compliance [39]

Wellbeing
during
pregnancy

Nested qualitative study
1. Focus group and information session given by
a midwife in the third trimester of pregnancy
a. Discussion on topics such as pain relief
options during labor and breastfeeding techniques

published online (https://www.canada.ca/en/health-canada/services/healthy-living/healthy-pregnancy.html).
After delivery, both study groups receive usual care
from their healthcare practitioners with no further
intervention; the research team prospectively follows
participants at three months and six months postpartum. Table 1 outlines the study arms.
Participants randomized to the personalized, monitored, and structured Nutrition + Exercise program
group (intervention) begin early in the second trimester
of their pregnancy until the end of pregnancy with counseling on a weekly or biweekly basis (Table 1 and Fig. 1).
The nutrition component is an individualized nutrition
plan tailored to each participant’s energy requirements
with a high protein content (25% protein energy) provided primarily by dairy foods. Dairy foods are accepted
by women during pregnancy as a healthy choice as indicated from our pilot study [36] and in a recent birth cohort study in the same community in which women

consumed an average of ≥ 3 servings of dairy foods per
day [37]. Dairy foods are sources of high-quality proteins, calcium, and vitamin D in the case of milk as it is
under mandatory fortification with vitamin D in Canada.
The Nutrition + Exercise intervention is considered safe.
First, the nutrient intake associated with the increased
low-fat dairy consumption is less than the tolerable
upper intake level for all nutrients as recommended per
the Dietary Reference Intake by Health Canada. In
addition, walking (the exercise component) is the easiest
physical activity to undertake and implement in terms of
goal-setting for step count and monitoring adherence
using accelerometer-type devices as demonstrated in our
previous studies [38–40]. Walking was the most practical exercise intervention of choice since women reduce
moderate and vigorous physical activity during pregnancy yet maintain levels of walking [41]. Most importantly, these exercise guidelines are based on the Physical
Activity Readiness Medical Examination (PARmed-X)
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Fig. 2 BHIP study protocol timeline

for Pregnancy [35]. Data from the Nutrition and Exercise Lifestyle Intervention Program study [39] indicates
that the goal of 10,000 daily steps is feasible under
free-living conditions and has been effectively utilized in
a number of trials [42].
A component of the intervention is discontinued if
the medical condition of a participant changes and the
intervention is modified if a participant requests a
change due to personal reasons, such as food aversion
or pain episode. The intervention is personalized for
every woman, to ensure the goal of 25% energy from
protein and 10,000 steps/day are achieved. Additionally, estimated energy requirements are calculated for
each mother using the equation derived in the Dietary
Reference Intake report for normal and overweight
women [43] with energy intakes adjusted as recommended in the second and third trimesters [17]. The
individualized nutrition plan is fashioned upon a
standard three-day food intake record completed by
the mothers that includes one weekend day as used
previously in pregnant women [39]. The individualized
nutrition plans and counseling are conducted by a
study nutritionist providing the number of food

servings to meet their estimated energy requirements.
The nutrition plan is modified if GWG monitoring indicates weight loss or excess gain has occurred as recommended in the GWG guidelines [17, 44]. Adverse
events related to the intervention are reported to our
local ethics boards. Other non-intervention-related adverse events are noted in the participant’s chart and
monitored, in accordance with the N2 Network of
Networks guidelines Canada [45].
Several strategies are used to improve adherence to
the intervention. For the exercise component, participants wear and track their step counts on a weekly basis,
increasing motivation and adherence to the treatment.
In addition, they go for a walk with the research staff
and have a personalized counseling session with the
study nutritionist. For the nutrition component, participants are provided with low-fat milk, cottage cheese,
and/or yogurt, as per their preference, to ensure they
consume the recommended amount of dairy foods. Participants come to the study site at least every other week
to receive their dairy foods and the study nutritionist
shares strategies and recipes with the participants to ensure they consume the targeted amount of dairy food
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servings. All these actions improved the adherence to
the study protocol.
Participants randomized to the usual care group (control) receive usual prenatal care. Participants are given
the most recent advice from Health Canada including
Healthy Weight Gain During Pregnancy [17], the Pregnancy Weight Gain Calculator [44], and Eating Well
with Canada’s Food Guide [46]. Mothers are followed by
their primary care provider who also receives the same
Health Canada materials. After delivery, they are
followed by their healthcare practitioners. In addition,
the control participants are invited to participate in a
focus group and to attend an information session led by
a midwife; topics discussed include pain relief options
during labor and breastfeeding techniques (Table 1).

Outcome measurements
Primary and secondary outcomes are summarized in
Table 2 and described below.
 Primary outcome

○ GWG

 Secondary outcomes

○ Maternal and cord blood circulating bone
markers: PINP, CTX-I, IGF-1, 25(OH)D,
1,25dihydroxyvitamin D
○ Maternal bone status at six months postpartum:
whole-body bone mineral content (BMC), whole
body BMD, lumbar spine BMD
○ Infant bone status at six months of age: whole
body minus the head BMC
 Other outcomes
○ Maternal body weight and fat mass
○ Maternal metabolic status (including fasting
glucose and lipid profiles, leptin and
adiponectin)
○ Maternal blood pressure
○ Maternal pregnancy outcomes such as
gestational diabetes and pre-eclampsia
○ Infant birth outcomes such as birth weight and
body fat mass at six months
○ Safety outcomes
○ Quality of life using the EQ-5D questionnaire
○ Healthcare costs
○ Maternal and cord blood gene variant profiles
Data and biosample collection

The pre-pregnancy BMI is calculated using the measured
weight at study entry minus the mother’s self-reported
GWG. Body weight is measured by trained research assistants using a body impedance Tanita Body Composition
Analyzer BF-350 scale (Tanita, IL, USA) at 12–17 weeks
of gestation, 26–28 weeks of gestation, 36–38 weeks of
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gestation, three months postpartum (self-reported weight
only), and six months postpartum. GWG is calculated by
subtracting the weight at the 36–38 weeks of gestation
study visit by the pre-pregnancy weight. Adjustments such
as rate of GWG will be made to account for gestational
age at delivery, including pre-term births.
Fasted maternal blood samples for metabolic and bone
health biomarkers are collected at 12–17 weeks of gestation, 36–38 weeks of gestation, and at six months postpartum; venous cord blood is collected at delivery.
Serum is collected in serum-separating with gel (SST™)
vacutainers and in spray-coated silica vacutainers;
plasma is collected in sodium fluoride/ Na2 ethylenediaminetetraacetic acid (Na2EDTA) vacutainers. Sample
are centrifuged for 10 min at 3000 rpm at 4 °C; serum
separator tubes are spun for an additional 5 min, aliquoted, and stored at − 80 °C. Samples are batched to include all samples from each mother for analysis in our
laboratories when participants have completed the study.
Fasting plasma glucose is determined using a hexokinase
photometric assay (Architect kit, Abbott, Abbott Park,
IL, USA). Serum triglycerides are analyzed using a glycerol phosphate oxidase photometric assay (Architect
kit, Abbott, Abbott Park, IL, USA) completed by
Hamilton Health Sciences Regional Laboratory Medicine
Program. Serum leptin and insulin are analyzed using
Luminex® human premixed multi-analyte enzyme-linked
immunosorbent assay (ELISA) kit supplied by R&D Systems (Minneapolis, MN, USA). Serum adiponectin and
C-reactive protein are analyzed by Luminex® premixed
multi-analyte ELISA kit supplied by R&D Systems. Bone
formation is assessed by measuring serum PINP by
ELISA (Cloud Clone Corp., Houston, TX, USA). Bone
resorption is assessed by measuring serum CTX-I by
(Serum Crosslaps (CTX-1) ELISA, product code
AC-02F1 Immunodiagnostic Systems, UK). Growth is
assessed by measuring serum IGF-1 by ELISA (R&D
Systems, Minneapolis, MN, USA). All standards and
samples are analyzed in duplicate, following the manufacturer’s instructions. A serum quality control is run in
triplicate at the beginning and end of each ELISA plate
to calculate inter- and intra-assay coefficients of variability. Serum vitamin D metabolites are measured by liquid
chromatography tandem mass spectrometry (LC-MS/
MS) using a Waters AQUITY Tandem Quadropole Detector coupled to an AQUITY UPLC system (Waters
Corporation), after extraction that includes a saponification step as adapted from Hymoller [47]. Accuracy is determined using the certified Vitamin D analytes
serum-based standard reference material (SRM 972a)
from the US National Institute for Standards and
Technology (NIST; National Bureau of Standards,
Washington, DC, USA) [48]. Precision is measured
using a serum quality control in all runs of samples
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Table 2 Analysis plan: objectives, outcomes, hypotheses, and methods of analysis
Objective

Hypothesis

Outcome measure (type of outcome:
B = binary or C = continuous)

Methods of analysis

1. Primary

An experimental combined Nutrition + Exercise
intervention will increase the percentage
of pregnant women who achieve GWG within
current recommendations when compared
with standard care provided in the primary
care community setting

Proportion of women who are within
the BMI appropriate GWG according
to the IOM guideline for GWGs (B)

Logistic regression

2. Secondary

An experimental combined Nutrition + Exercise
intervention will lead to better maternal and child
bone health outcomes when compared to
standard care

3. Subgroup
analyses

The percentage of women within each
of the normal, overweight, and obese
BMI categories will be similar with respect
to being with the IOM target GWG for
each category

Proportion of women in each BMI category
who reach appropriate GWG according
to the IOM guideline for GWGs

4. Sensitivity
analyses

Combined Nutrition + Exercise Intervention leads
to a greater percentage of women who achieve
GWG within current recommendations when
compared to standard care

Primary outcome only

• Maternal and cord blood circulating
bone markers (C)
○ Bone biomarkers: PINP, CTX-I, IGF-1,
25(OH)D, 1,25(OH)2D
• Maternal bone status at 6 months
postpartum (C)
○ Whole body bone mineral content,
whole body BMD, lumbar spine bone
mineral density by DXA scan
• Maternal fat mass (C)
• Maternal blood glucose, lipid profile,
leptin, and adiponectin
• Maternal blood pressure (C)
○ Diastolic BP
○ Systolic BP
• Maternal pregnancy outcomes (B)
○ Gestational diabetes
○ Pre-eclampsia
• Infant bone status at 6 months of age (C)
○ Whole body minus the head bone
mineral content by DXA scan
• Infant outcomes
○ Birth weight z-score(C)
○ Body fat mass (B)

Regression analysis
*We will use logistic regression
for binary outcomes and
linear regression for continuous
outcomes

Regression analysis including
the interaction term of BMI
group X Intervention group

• Generalized estimating
equations
• Random-effects model

IMPORTANT REMARKS:
In all analyses, results will be expressed as difference or OR (95% CI) and associated p values, as appropriate
Bonferroni method will be used to adjust the overall level of significance for multiple secondary outcomes
We will examine residuals to assess model assumptions
The GEE [76] is a technique that allows to specify the correlation structure between patients within a site and this approach produces unbiased estimates under
the assumption that missing observations will be missing at random. An amended approach of weighted GEE will be employed if missingness is found not to be
at random [77]
*Infant growth outcomes at 6 months will be adjusted for feeding type (duration of breast feeding from birth to 6 months)

tested, allowing calculation of inter- and intra-assay coefficients of variability.
DNA extracted from maternal and cord blood plasma
samples will be purified using the Chemagen 500 MSM I
(PerkinElmer chemagen Technologie GmbH, Baesweiler,
Germany) and genotyped using the Human Core Exome
Bead Chip by Illumina. The chip is specifically designed to
allow imputation of up to 18 million markers in
multi-ethnic populations. Data cleaning and quality control of SNPs data are done according to the guidelines
published by Winkler et al. [49].

Bone mass is measured by DXA scan using the research dedicated QDR®4500 series Hologic Inc. Discovery™ DXA machine (Waltham, MA, USA; Adult whole
body software version 12.3.1 and Infant whole body software) at the McMaster University study site and the
General Electric-Luna iDXA (Ames Medical enCORE,
Version 14.1, Waukesha, WI, USA; CoreScan, GE) at the
Western University study site. Daily quality control tests
are conducted using an artificial L1–4 lumbar spine made
from hydroxyapatite encased in epoxyresin. Weekly, a
calibration test is performed using a step phantom
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(composed of soft-tissue and lean-tissue equivalent materials); at this time, the uniformity test is also performed to evaluate the contribution of air molecules to
the attenuation of the X-rays. The coefficient of variations for BMC and BMD were 0.65% and 0.38%, respectively (Hologic Inc., Bedford, MA, USA) in our past study
[37]. Inter-site comparison of DXA measures is conducted by having two phantoms (i.e. Hologic lumbar
spine phantom (#2603), BFP® phantom) tested at both
study sites. This provides a cross-calibration standard
and enables us to account for inter-site differences and
to harmonize results. It also allows for verification of the
instrument stability over the course of the study.
At six months postpartum, bone scans are performed on
mothers and infants at six months by staff following a
standard operating procedure. Mothers are dressed in
regular clothes without any metal parts or in a light hospital gown, while infants are in a clean diaper only. The
primary outcome assessor, who has expertise in analyzing
DXA scans, reviews all scans from both study sites. This
ensures consistency in analysis across all participants at
both study sites. If objects are included in the scan such as
a child’s toy, a sub-regional analysis is done to isolate and
subtract the object’s contribution to overall results. If considerable movement artifacts are seen in infant scans, the
well-captured limb is used as a surrogate for the one with
movement [50]. Any scans with unsalvageable distortions
due to movement are not included. Z-scores are calculated for all BMC and BMD results using data from an
age- and sex-specific standard curve. Results for women
are interpreted as z-scores in reference to an adult women
population embedded in the Hologic software. Results for
infants are expressed as whole body minus the head BMC
and BMD. Data are interpreted as z-scores in reference to
an infant population from in-house data collection on
normal healthy term infants from birth to one year of age.
All participants receive instructions to complete a
standard three-day food intake record at 12–17 weeks of
gestation, 26–28 weeks of gestation, 36–38 weeks of gestation, and six months postpartum. The food record includes two weekdays and one weekend day, as used
previously in pregnant women [39]. It captures food and
beverage intake as well as drug and supplement (vitamin
and mineral) intake. Trained assessors analyze all food
records using standard operating procedure on the
computer-based Nutritionist Pro Software (Axxya Systems, Stafford, TX, USA). Nutritionist Pro computes the
average amount of nutrients consumed per day.
Physical activity level is assessed through wearing a
BodyMedia Sensewear Pro II armband monitor device
(BodyMedia, Pittsburgh, PA, USA) in all participants
for the same three days (as food monitoring above) in
their work/home environment. These small devices
are comfortable and easily wearable on the arm [38].
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The data collected for three days at each visit (12–17,
26–28, and 36–38 weeks of gestation and six months
postpartum) includes daily steps, daily energy expenditure, and minutes of activity level in Metabolic
Equivalent of Task (MET; very vigorous, vigorous,
moderate, sedentary). The Sensewear unit does not
provide feedback to the participant.
Pregnancy and infant outcomes are obtained from participant’s medical records. Details are extracted about
Cesarean section and/or vaginal delivery. For infant outcomes, data regarding gestational age, birth weight, birth
length, birth head circumference, 1-min and 5-min
Apgar scores, complications related to birth, and feeding
practices at birth are extracted.
Infant weight and length at birth are recorded from
medical charts and at three months of age as reported by
the mother during the telephone interview. At the
six-month visit, trained assessors measure infant weight
by electronic scale (Medela BabyWeigh, McHenry, IL,
USA), length using a measuring board for term infants
(Pediatric Stadiometer, Ellard Instrumentation Ltd.,
Monroe, WA, USA), and head circumference using a
constant-tension measuring tape (OHAUS, Dundas, ON,
Canada), following standard operating procedures.
Infant feeding practices over the first three months
are recorded by phone call and at six months in person using a standardized questionnaire administered
by a trained assessor [51]. The questionnaire includes
feeding history, duration and extent of breastfeeding,
introduction of solid foods, and use of vitamins and
supplements.
Study management and governance

This RCT is led by investigators from McMaster University (Department of Pediatrics, Department of Family
Medicine, Department of Obstetrics and Gynecology,
Department of Health Research Methods, Evidence and
Impact, and School of Nursing) and Western University
(School of Kinesiology) as well as practitioners from the
City of Hamilton Public Health, all located in Ontario,
Canada. The oversight of the study is guided by the steering committee that is composed of the lead investigators
(SAA, SMP, MFM, LT, and EKH). The sponsors of the
study are McMaster University and Western University.
The sponsors are indemnified for any harms arising from
trial participation and they approve protocol amendments
when ethics approval has been obtained. Day-to-day running of the study is provided by the trial principal investigators, the study coordinators, and research assistants.
The monitoring board consists of three well-established
investigators from universities within Canada but outside
McMaster and Western Universities.
All case report forms are anonymized using study
identifiers and are stored in locked cabinets in a locked
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office. An administrative assistant to the study team who
is not involved in the study holds the key to participants’
names. Research staff who are not involved in data collection enter data in a two-step process (entry and verification, following standard operating procedures) in our
REDCap projects hosted at McMaster University [52].
REDCap is a secure, web-based application designed to
support data capture for research studies, providing: (1)
an intuitive interface for validated data entry; (2) audit
trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless
data downloads to common statistical packages; and (4)
procedures for importing data from external sources.
Use of range check for data values promotes data quality. Double data entry is performed to ensure inter-study
site reliability.
The research assistant monitors intervention adherence
biweekly. For the nutrition portion, this includes ensuring
dietary intake meets each participant’s caloric needs and
are within an acceptable macronutrient distribution range.
In terms of the exercise portion, participants monitor and
report biweekly their physical activity using a diary and by
wearing a pedometer. Participants report any discomfort
experienced (due to the natural course of pregnancy and/
or the intervention) to the study coordinator who personalizes the intervention as needed.

Statistical methods

The analysis and reporting of the results will follow the
SPIRIT statement for reporting RCTs [53]. The process
of patient selection and flow throughout the study will
be summarized using a flow-diagram (Fig. 2).
The results of patient baseline characteristics and outcome variables (both primary and secondary) will be
summarized using descriptive summary measures:
expressed as mean (standard deviation) or median
(range) for continuous variables and n (%) for categorical
variables. All statistical tests will be performed using
two-sided tests at the 0.05 level of significance. Binary
outcomes will be analyzed using logistic regression and
continuous outcomes will be analyzed using linear regression. All analyses will account for stratification by
including study site and participants’ BMI category in
the models. For all models, the results will be expressed
as estimate of the difference for continuous outcomes
(odds ratio [OR] or relative risk [RR] for binary outcomes), corresponding two-sided 95% confidence intervals (CI) and associated p values. P values will be
reported to three decimal places with values < 0.001 reported as < 0.001. The Hosmer–Lemshow will be used
to assess goodness-of-fit for logistic regression and explore the residuals to assess goodness-of-fit and model
assumptions for linear regression.
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An intention-to-treat principle will be adopted to
analyze all outcomes. Multiple-imputation will also be
used to handle missing data during data collection. Sensitivity analyses will be performed using some of the
commonly used RCT patient-level methods (e.g. generalized estimating equations, the random-effect model
which account for the potential correlation within sites,
etc.) to assess the robustness of the results [54]. All the
analyses will be done using SAS 9.2 (Cary, NC, USA) or
SPSS 13 (Chicago, IL, USA). Table 2 provides a summary of the planned methods of analyses for each outcome and subgroup.
Power calculation

The sample size calculation for the core study is based
on the test of the null hypothesis that the percentages of
women with GWG within IOM guidelines in the two
populations (intervention and control) are equal. To account for the uncertainty in these prior estimates, we
calculated the sample size for different values of the percentage of women with weight within IOM guidelines in
the control group in the range of 50–65%, with a risk
difference of 15%, 20%, 25%, and 30%. While initially we
targeted a total sample size of 350, the constraints of our
funding timelines (which include a one-year CHIR grant
extension) and a recruitment rate that was less than projected despite our best efforts, we revised our desired
sample size to 242. Based on our a priori calculation, a
sample size 111 per group corresponds to an absolute
difference of 30% with our Nutrition + Exercise intervention, resulting in 30% of women in the treatment
group having a GWG exceeding the IOM recommendations compared to 65% in the control group. With the
revised sample size (i.e. assuming a 1:1 allocation ratio),
the study will have power of 80% to yield a statistically
significant result assuming a binomial distribution (using
an intention-to-treat principle for the analysis) of the
difference between percentages of women with GWG
within IOM guidelines at alpha = 0.05. We hope to increase the sample size to 242 total participants in order
to allow us to account for the two stratification variables
– site (2 degrees of freedom) and baseline BMI strata (3
degrees of freedom).
The calculated sample size for the secondary outcome
of maternal bone biomarker status is a total of 177 participants (allocation 1:1, α = 0.05, β = 20 for two-group t-test),
based on literature with similar outcomes [55, 56]. A sample size was also calculated for the secondary outcome of
infant whole body minus the head BMD. The total is 240
participants (allocation 1:1, α = 0.05, β = 20 for two-group
t-test) based on the literature with similar primary outcomes in infant populations [57, 58]. For both sample
sizes, a 15% attrition rate was calculated as a precaution in
this type of clinical trial with follow-up.
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Discussion
The BHIP study is novel as it proposes a feasible Nutrition + Exercise intervention that pregnant women could
incorporate into their lifestyle and improve adherence to
GWG recommendations. In addition, it will contribute
to the knowledge of the perinatal developmental programming of body composition and skeletal phenotypes.
The BHIP RCT enrolls women in early pregnancy
(12–17 weeks of gestation). Ideally, women should have
access to general health interventions before pregnancy;
however, currently pregnancy is often the first opportunity for health professionals to address issues beyond
those directly related to the pregnancy state. Thus, one
of the strengths of the BHIP study is that it starts in
early pregnancy and monitors participants until six
months postpartum. In addition, measures of health outcomes in both mother and child at various time points
throughout pregnancy and postpartum allow for a comprehensive evaluation of the intervention effects. Lastly,
one particular strength of the BHIP study is the individualized intervention and weekly monitoring. Evidence
shows that the consumption of dairy foods (nutrition
component) is well accepted during pregnancy [36], while
walking (exercise component) is the best physical activity
to promote adherence during pregnancy [38–40].
The primary outcome of GWG was selected because it
is the key clinical problem we are addressing with our
Nutrition + Exercise intervention. Pre-pregnancy obesity
and excess GWG are the strongest maternal characteristics associated with offspring obesity [9, 11, 59] and
childhood metabolic dysfunction [60]. Excess GWG in
pregnancy is a major clinical challenge affecting Canadian
women who enter pregnancy overweight and even women
of normal pre-pregnancy weight [61, 62]. At the national
level, a cross-sectional study on pregnancy experiences in
Canada determined that over one-third of women entered
pregnancy overweight or obese and nearly 60% experienced GWG greater than that recommended by the IOM
recommendations for GWG [63]. The Alberta Pregnancy
Outcomes and Nutrition prospective cohort study reported similar statistics with a greater number of overweight and obese women (80%) gaining excess weight
during pregnancy [64]. Likewise, in the Hamilton region, data from the Family Atherosclerosis Monitoring
In earLY life birth cohort demonstrated that > 50% of
women entered pregnancy with a pre-pregnancy BMI
of > 25.0 kg/m2 and > 50% exceeded the IOM guidelines
for GWG [65]. Evidence to date suggest that the most
convincing approach to achieve appropriate GWG is an
intervention combining physical activity and nutrition,
in combination with weight monitoring [1, 20, 21].
The secondary outcome of bone status was selected
due to the emerging evidence of risk of osteoporosis in
later life being programmed from the womb [24]. Bone
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biomarkers were selected as outcomes following the
International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine recommendations, which is to measure a
marker of bone formation and a marker of bone resorption to assess bone turnover [66]. Currently, the most
sensitive markers recommended are subgroups of type I
collagen representing the predominant component of
the bone matrix wherein sub-products can be measured
as markers of formation and resorption of the bone [66].
To support fetal bone growth, pregnant women undergo
bone metabolic adaptations over the course of pregnancy, where bone resorption usually rises and formation declines [67]. These changes result in high bone
turnover during pregnancy [68]. Maternal bone turnover
peaks during the third trimester, with a marked increase
in bone resorption observed at 38 weeks of gestation
[69]. Based on this knowledge, two biomarkers of bone
modelling are quantified in maternal blood at 36–38
weeks of gestation and in cord blood. The marker of
bone formation is PINP and the marker of bone resorption is CTX-I. Blood samples are consistently collected
in a fasted state and in the morning, as suggested by the
National Bone Health Alliance [70]. In addition, vitamin
D status is measured by serum 25(OH)D as it plays an important role in calcium homeostasis and bone metabolism
[71] and is a reflection of dietary vitamin D intake and sun
exposure. Both the frequency of milk consumption and
sun exposure were shown to be positive predictors of
serum 25(OH)D concentrations in the recent multivariate
analysis of three cycles of the Canadian Community
Health Measures surveys [72]. The active form of vitamin
D, 1,25dihydroxyvitamin D, is also measured since it is
known to be upregulated during pregnancy [73].
Bone mineral content was selected as an outcome because it is linked to the peak bone mass (i.e. highest
bone mass accrued for an individual) and is predictive of
osteoporotic fracture [32]. Furthermore, recent evidence
suggests that childhood BMC persists until peak bone
mass and could indicate individuals at risk of osteoporotic fracture [31].
The nature of the intervention brings a limitation; the
research study personnel in direct contact with the participants are not blinded to the study allocation of each
participant. To preserve the integrity of the study findings and the internal validity of the study, all other investigators and statisticians are blinded to the study
allocation, including people collecting and performing
the analysis of primary and secondary outcomes. Some
sources of bias are inevitable in the context of the study:
recruitment sites are mostly primary care clinics, with
few participants recruited from advertisements in the
community. Since women are excluded with limited
comprehension of the English language, if documented
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signs of depression or a pre-pregnancy BMI > 40 kg/m2,
the generalization of the study would exclude such
groups. From previous studies completed in urban
Southern Ontario [39, 65] we anticipate that our study
population will be mostly Caucasian, holding a university
degree, and with a medium to high socioeconomic status. This sample is representative of the populations in
the cities were recruitment occurred as they are modern urban centers with universities, colleges, and major
commerce. Thus, the results will be generalizable to
populations of women living in many Canadian cities
with academic centers and major commerce. In
addition, our results will still be of high value for the
general Canadian pregnant women population who are
served through provincial public health units, as it will
bring new knowledge to refine the Canada Prenatal
Nutrition Program (CPNP, https://www.canada.ca/en/
public-health/services/health-promotion/childhood-ado
lescence/programs-initiatives/canada-prenatal-nutrition
-program-cpnp.html), which is currently offered
through public health but not based on evidence.
The strengths of the design include that the Nutrition + Exercise intervention was vetted for feasibility
in pregnant women and care providers through focus
groups and was conducted in pregnant women of all
pre-pregnancy BMI categories (except extreme obesity) and in a community setting (as opposed to
hospital-based as in many reported studies).
For the timely recruitment of study participants, challenges included prolonged ethics approval processes at
secondary recruitment sites, reduced recruitment at
community family practices due to influx of immigrants
who were non-English speaking (thus not eligible), and
competition with other studies sampling pregnant
women. In light of these, we have taken measures to
achieve the predetermined sample size based on a power
analysis for the primary outcome so that the integrity of
the study is preserved and the results are able to properly test the stated hypothesis and provide the needed
new knowledge. To expand recruitment at McMaster
University a new local study site was set up in a nearby
city, Burlington, Ontario, with the collaboration of midwifery and obstetric clinics, as well as the local hospital.
This partnership is very successful thus helping to
achieve the recruitment goal. To date, retention after
randomization to the study visit at 36–38 week of gestation when we assessed our primary outcome is 87%. To
maximize retention of participants, we implemented a
number of procedures such as study visit times at the
convenience of the participants, including home visits.
We also offered in-person, over the phone, and email
correspondence to keep participants engaged. For
participants in the intervention group, providing them
with the dairy products (which are an integral part of
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the intervention) increases the likelihood of consuming
the recommended amount. For the exercise component,
participants receive a free pedometer as a self-motivation tool to reach their step count goals. Lastly, for
both groups, participants are compensated on three occasions with $25 gift cards that they can redeem at a
local grocery store.
If effective, this RCT will generate high-quality evidence to refine the nutrition guidelines during pregnancy to improve health of women during pregnancy
and their offspring in early life, including acquisition of a
strong skeleton.

Trial status
Active recruitment continues since a no-cost extension
of one year from CIHR was obtained in December 2016,
to allow the BHP study to achieve the target sample size.
Additional file
Additional file 1: SPIRIT checklist. (DOCX 76 kb)
Additional file 2: WHO Trial registration data set. (DOCX 18 kb)
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